ClinicalTrials.gg
RecruitingNCT07145112Updated Sep 28, 2026

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma

A Phase 1 interventional study of Laser interstitial thermal therapy and Lomustine in Glioblastoma, sponsored by University of California, Davis. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University of California, Davis · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Sep 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lomustine in Glioblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Lomustine · Glioblastoma.

Planned enrollment
17th of 22
25 · median 68
Started
2025
with 1 other
Phase 1
4 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies testing lomustine in Glioblastoma, this one is the 17th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 22nd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 22 studies testing lomustine in Glioblastoma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lomustine

Lomustine: first FDA approval 1976 (GLEOSTINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lomustine in Glioblastoma, or all of them as a file.
02

Study summary

This is a phase 1 study evaluating the safety and feasibility of laser interstitial thermal therapy (LITT) followed by lomustine (CCNU) for recurrent glioblastoma in adults. The primary aim is to evaluate the safety of the combination of LITT plus lomustine based on the assessment of treatment-related adverse events and the feasibility of completing LITT + lomustine in the proposed timeframe. The secondary aim is to assess overall survival for up to 2 years after the first dose of lomustine.

Read the detailed description

The LITT procedure is performed per standard of care under general anesthesia using a stereotactic neurosurgical approach where a laser catheter is precisely inserted into the tumor under MRI guidance. Real-time MRI thermometry is used to ensure controlled tumor ablation while minimizing damage to adjacent structures. Patients typically undergo postoperative MRI to assess treatment response, and most can be discharged within 24-48 hours, facilitating early initiation of adjuvant therapy.

Approximately 7 days following LITT, lomustine is administered per standard of care on Day 1 for a total of one cycle.

Participants will be monitored for serious and non-serious adverse events (AE) starting from initiation of LITT per institutional practices. All follow-up is based on standard of care for LITT and lomustine.

03

Conditions studied

  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed World Health Organization (WHO) 2021 defined glioblastoma. A pathology report constitutes adequate documentation of histology for study inclusion.
  2. Radiographic demonstration of disease progression following prior therapy.
  3. Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as the patient has recovered from surgery. Evaluable or following resection of recurrent tumor is not mandated for eligibility into the study.
  4. Prior standard radiation for glioblastoma (short course 40 Gy, standard 60 Gy, and proton therapy are allowed).
  5. Patients must have recovered from the effects of prior therapy.
  6. The following listed agents/interventions must have been discontinued for their respective time period prior to enrollment:

    1. Four weeks from cytotoxic agents (3 weeks from procarbazine, 3 weeks from vincristine, and 4 weeks from temozolomide);
    2. Four weeks or 5 drug half-lives (whichever is shorter) from any agent; two weeks or 5 drug half-lives (whichever is shorter) from non-cytotoxic agents (e.g. Accutane, thalidomide);
    3. Twelve weeks from radiotherapy to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progressive disease, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field;
  7. Patients must have the following laboratory parameters ≤ 14 days prior to registration:

    a. adequate bone marrow function defined by: i. white blood cells (WBC) ≥ 3 × 109/L , ii. (ANC) ≥ 1.5 × 109/L , iii. count of ≥ 100 × 109/L , and iv. ≥ 9 gm/dL b. adequate liver function defined by i. (ALT, SGPT) and aspartate transaminase (AST/SGOT) \< 3× institutional (ULN), ii. alkaline phosphatase \< 2× ULN, and iii. \< 1.5 mg/dL c. adequate renal function defined by calculated ≥ 60 mL/min (see Appendix)

  8. performance status (KPS) ≥ 50 (see Appendix).
  9. Individuals of or those with partners of childbearing potential must agree to use adequate methods of for the duration of study participation (including dosing interruptions) and for up to 3.5 months after the last study treatment; or be surgically sterilized.
  10. Patients on the following medications are allowed:

    1. Anticoagulants: Patients on stable dose anticoagulants (e.g. warfarin in-range [INR], low molecular-weight heparin)
    2. Patients are allowed to take aspirin, clopidogrel, ticlopidine, Aggrenox, ibuprofen and other NSAIDS.
  11. Patients must be willing to forego other cytotoxic and non-cytotoxic drug therapy for glioblastoma while enrolled in the study.
  12. Able to swallow oral medication.
  13. Patients ≥18 years of age at time of consent.
  14. Ability to understand and willingness to sign an form (ICF).
  15. Ability and stated willingness to adhere to the study visit schedule and protocol procedures/requirements, including periodic blood sampling and study related assessments

Exclusion criteria

Exclusion Criteria:

  1. Patients who are not surgical candidates for stereotactic or laser ablation.
  2. Prior treatment with nitrosourea agents (e.g. lomustine [CCNU], carmustine [BCNU], nimustine [ACNU]).
  3. Prior treatment with polifeprosan 20 with carmustine wafer.
  4. Prior treatment with bevacizumab.
  5. Patients who have received any agents ≤ 4 weeks or 5 drug half-lives (whichever is shorter) prior to commencing study treatment.
  6. Evidence of recent hemorrhage on baseline MRI of the brain with the following exceptions: (1) presence of hemosiderin, (2) resolving hemorrhagic changes related to surgery, or (3) presence of punctate hemorrhage in the tumor.
  7. History of intracerebral abscess within 6 months prior to Day 1.
  8. Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days prior to Day 1, or anticipation of the need for a major surgical procedure during the course of the study.
  9. Serious non-healing wound, ulcer, or bone fracture.
  10. Pregnancy (positive pregnancy test) or lactation.
  11. Known to any component of lomustine (CCNU).
  12. Uncontrolled intercurrent illness or unstable systemic disease, including, but not limited to, ongoing or active infection, uncontrolled hypertension, or serious cardiac arrhythmia requiring medication that would interfere with participant safety or limit compliance with the study requirements.
  13. Unable to undergo an MRI with contrast.
  14. Known allergy to nitrosoureas (e.g., lomustine, carmustine, nimustine).
  15. Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)

    Laser interstitial thermal therapy (LITT) + Lomustine (CCNU)

    Procedure: Laser interstitial thermal therapy · Drug: Lomustine

Interventions

  • ProcedureLaser interstitial thermal therapy

    MRI guided laser

    Also known as: LITT

  • Given orally (PO)

    Also known as: CCNU, Gleostine

06

What researchers measure

Primary outcomes

  1. Safety of the combination of Laser Interstitial Thermal Therapy (LITT) and lomustine in patients with recurrent glioblastoma.

    Number of treatment related adverse events, grade 3 and 4 using Common Terminology Criteria for Adverse Events (CTCAE) version 5.

    Time frame: Up to 6 weeks after first dose of lomustine

  2. Tolerability of the combination of Laser Interstitial Thermal Therapy (LITT) and lomustine in patients with recurrent glioblastoma.

    Percentage of participants completing LITT and receiving 1 dose of lomustine within the proposed timeframe (e.g., 7 days).

    Time frame: Up to 7 days post laser uinterstitial thermal therapy

Secondary outcomes

  1. Overall survival

    Median time of presentation to date of death or censored at last follow-up date.

    Time frame: Up to 2 years following first dose of lomustine.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 17 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jul 2027 → Mar 2027 and completion Dec 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 28, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Mar 2027was Jul 2027
CompletionEst.
Sep 2027was Dec 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2027→Mar 2027
Sep 28, 2026
Study completion
Dec 2027→Sep 2027
Sep 28, 2026
Enrollment
20→25
Sep 28, 2026
Contact
Study contact changed: o•••@health.ucdavis.edu · •••3772→O•••@health.ucdavis.edu · •••6970. See the current contact
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Jul 2027→Mar 2027
    Study completion Dec 2027→Sep 2027
    Enrollment 20→25
    Contact Study contact changed: o•••@health.ucdavis.edu · •••3772→O•••@health.ucdavis.edu · •••6970. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07145112
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Oct 1, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

Office of Clinical Research
Contact
OCRReferral@health.ucdavis.edu
916-382-6970
Orwa Aboud, MD, PhD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lomustine

Start the discussion